PALB2 and breast carcinoma: Heikkinen et al. also showed that PALB2-mutated breast cancer patients were more likely to present at an advanced disease stage (p = 0.0027 and p = 0.0017, respectively) and have a higher Ki67 level (p = 0.0004 and p = 0.0490, respectively) compared with other familial or sporadic patients (80).